TATri Murti Andayani

Tri Murti Andayani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tri Murti Andayani has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Suspected fentanyl–midazolam adverse drug reactions, mainly bradypnea and bradycardia, are associated with prolonged intensive care unit stay in mechanically ventilated patients

    by Windy Septiyanti, Ika Puspita Sari, Tri Murti Andayani

    Background: Fentanyl–midazolam remains a common analgosedation regimen for mechanically ventilated patients in many intensive care units (ICUs). Its adverse drug reactions (ADRs) may prolong ICU length of stay (LOS), but evidence is limited, particularly in Indonesia. Objective: To describe suspected ADRs associated with fentanyl–midazolam and their association with ICU LOS in mechanically ventilated patients. Methods: This retrospective cohort study reviewed records of adults receiving mechanical ventilation and continuous fentanyl–midazolam infusion in the ICU of an Indonesian academic hospital from January 2022 to April 2023. Of 460 patients screened, 80 were analyzed (40 with and 40 without suspected ADRs). Causality was assessed with the World Health Organization–Uppsala Monitoring Centre system and severity with the Hartwig scale. Prolonged LOS was defined as ≥3 days. Associations were tested with the chi-square test and expressed as risk ratios (RRs). Results: Among the 40 patients with suspected ADRs, the most frequent reactions were bradypnea (17/40, 42.5%), bradycardia (14/40, 35.0%), and apnea (4/40, 10.0%). Causality was probable in 27 patients (67.5%) and possible in 13 (32.5%), and 36 reactions (90.0%) were Hartwig level 1. Prolonged LOS occurred in 32 of 40 patients (80.0%) with ADRs and 22 of 40 (55.0%) without ADRs (p = 0.017; RR 1.45; 95% CI 1.06–2.00). Conclusion: Suspected fentanyl–midazolam ADRs, mostly mild respiratory depression and bradycardia, were associated with prolonged ICU stay. Close respiratory and hemodynamic monitoring and careful dose titration are warranted.

  • Self-reported questionnaires for assessing medication adherence in coronary heart disease patients: A systematic review

    by Maya Arfania, Tri Murti Andayani, Anna Wahyuni Widayanti, Nahar Taufiq

    Medication adherence is essential for assessing the effectiveness of treatment in people with coronary heart disease (CHD). It is evaluated through self-report, which is the most economical and straightforward method. This systematic review aimed to identify validated self-report questionnaires that measure medication adherence in patients with CHD.The study adhered to the PRISMA guidelines for carrying out systematic reviews. A total of 23 articles were selected according to the inclusion criteria, from three databases, namely PubMed, ScienceDirect, and Scopus. The Joanna Briggs Institute (JBI) Critical Appraisal Instrument was used to independently evaluate the quality of the included articles. The most generally used self-report questionnaires for assessing medication adherence in patients with CHD were the MMAS-4 and MMAS-8, each applied in 22% of the studies. These were followed by the MARS-5, MGLS, and ACDS, each used in 13% of the studies. The results showed that most questionnaires had acceptable reliability (Cronbach’s α = 0.739–0.898) and validity (content and construct). However, few articles evaluated questionnaires across diverse cultural contexts or assessed their sensitivity to partial or intermittent medication adherence. The MMAS-4 and MMAS-8 were the most commonly used validated self-report adherence questionnaires. Despite presenting acceptable psychometric properties, questionnaires had limited cultural adaptation and sensitivity to partial or intermittent adherence. This emphasized the need for further validation and the development of tools better tailored to diverse clinical settings and study contexts.

  • Open Access

    Population Pharmacokinetic-Based Model-Informed Precision Dosing: Current Implementation Status and Global Equity Gaps – A Structured Narrative Review

    by Novia Dani Aisyah, Akhmad Kharis Nugroho, Tri Murti Andayani

    Background: Model-Informed Precision Dosing (MIPD) leverages population pharmacokinetics (PopPK) and Bayesian forecasting to optimise drug therapy in heterogeneous populations. Despite its theoretical promise, real-world implementation remains limited, particularly in low- and middle-income countries (LMICs). Objective: This review synthesises evidence on the clinical integration, outcomes, enablers, and barriers of population pharmacokinetic (PopPK)-based MIPD. Methods: A structured narrative review was conducted across five databases to identify studies reporting real-world PopPK implementation (2014-2025) in clinical settings. Results: Twenty-seven studies were included, predominantly from high-income countries (HICs). Antibiotics were the most studied drug class, particularly vancomycin, which dominated the therapeutic areas studied; however, routine clinical implementation remained minimal. MIPD improved pharmacokinetic target attainment, reduced ICU stay by 2.13 days, and generated cost savings of up to $12,324 per patient. Key enablers included clinician-pharmacist collaboration and user-friendly software, whereas barriers included inadequate therapeutic drug monitoring (TDM) infrastructure and digital disparities in LMICs. Conclusion: PopPK-based MIPD demonstrates clinical and economic benefits but faces significant global implementation challenges. Accessible software development, TDM infrastructure enhancement, and validation studies in underrepresented populations are essential.


  • Open Access

    Measurement Quality of Life in People with Diabetes Mellitus using EQ-5D-5L, SF-6D, and QWB-SA

    by Akbar Nugraha, Dwi Endarti, Tri Murti Andayani

    Background: Quality of life is considered a humanistic outcome that can be used as a utility value in cost-utility analysis to compare therapeutic interventions. Diabetes mellitus can affect quality of life Objective: This study aimed to assess the utility values among patients diagnosed with diabetes mellitus and examine their correlation with patient characteristics. This study provides the first comparison of utility values derived from the EQ-5D-5L, SF-6D, and QWB-SA among Indonesian patients with diabetes mellitus in a primary care setting, offering locally relevant evidence for cost-utility analyses and highlighting the sociodemographic and clinical factors influencing QoL. Methods: Utility values were measured using the EuroQol Five-Dimension Five-Level (EQ-5D-5L), Short Form Six-Dimension (SF-6D), and Quality of Well-Being Self-Administered Scale (QWB-SA). The research design was cross-sectional, with a sample of Prolanis program members from community health centers in Gunung Kidul, Surakarta, Surabaya, and Madiun. Patient responses were converted to utility scores. Correlations between utility values and patient characteristics were analyzed using the Mann–Whitney or independent t-tests. Results: Utility scores obtained from EQ-5D-5L, SF-6D, and QWB-SA showed significant differences across instruments, with mean values of 0.89 ± 0.1575, 0.92 ± 0.0932, and 0.66 ± 0.1229, respectively. Conclusion: The utility scores of patients with diabetes mellitus measured using the EQ-5D-5L, SF-6D, and QWB-SA questionnaires showed significant differences. Patient characteristics that significantly influenced utility values included education level, employment status, income level, blood glucose control, and the presence of comorbidities.

  • Open Access

    Cost-effectiveness of immune checkpoint inhibitors and chemotherapy in triple-negative breast cancer: a scoping review

    by Bernadeta Setyo Venanti, Rizky Danang Susetyo, Hilmy Irsyadi Hanif, Tri Murti Andayani, Zullies Ikawati

    Triple-negative breast cancer (TNBC) is an aggressive malignancy associated with poor clinical outcomes and substantial economic burden. Standard chemotherapy treatment offers limited survival benefits, whereas immune checkpoint inhibitors (ICIs) have broadened therapeutic options. This review evaluates the cost-effectiveness of ICIs compared to conventional chemotherapy in TNBC and aims to identify which ICI provides the most favorable economic value. Using the PICO framework, which focuses on TNBC patients receiving chemotherapy as intervention and ICIs as comparators. The primary outcomes include incremental cost-effectiveness ratio (ICER), quality-adjusted life years (QALYs), and/or life years gained (LYG). Thearticles were selected based on the PRISMA strategy. A comprehensive selection of articles published from January 2020 to December 2024 was analyzed from PubMed, Google Scholar, Cochrane, and Scopus. TNBC commonly shows high tumor T-cell infiltration and Programmed Death Ligand-1 (PD-L1) expression, making ICIs such as atezolizumab and pembrolizumab viable treatment options. Atezolizumab improvedprogression-free survival (PFS) but was not found to be cost-effective in Singapore or the U.S. Pembrolizumab, however, significantly improved event-free survival (EFS) and demonstrated cost-effective across multiple countries, including Egypt, the United States of America (USA), and Switzerland. Sacituzumab govitecan, despitesurvival benefits in metastatic TNBC, showed high ICERs and poor cost-effectiveness. Pembrolizumab combined with chemotherapy appears to be more cost-effective than atezolizumab for PD-L1-positive TNBC patients. Meanwhile, sacituzumab govitecan has not been demonstrated to be cost-effective.

  • Open Access

    Cost-effectiveness analysis of colonoscopy for screening colorectal cancer in Indonesia using Markov Model

    by I Kadek Suardiana, Dwi Endarti, Tri Murti Andayani

    Colorectal cancer (CRC) is one of the top three diagnosed cancers worldwide and the second leading cause of cancer-related deaths, imposing a significant economic burden. In this context, early detection is crucial for effective management. The primary detection method particularly for high-risk individuals is colonoscopy but screening has not been widely adopted and the participation rate and the colonoscopy screening compliance rate were low. Pharmacoeconomic investigations are essential for evaluating the costs and effectiveness of colonoscopy screening for colorectal cancer. Therefore, this research aimed to conduct a cost-effectiveness analysis using a Markov model for a cohort of 100,000 adults aged 45 to compare the outcomes of screened and unscreened scenarios. The Markov model developed in this study consists of three main stages: the health stage, the colorectal cancer stage, and the death stage. The parameters used in this study include the probabilities at each stage, costs, the sensitivity and specificity of colonoscopy, utilities at each stage, and the discount rate. One-way and probabilistic sensitivity analyses were conducted to address uncertainty. Meanwhile, the Incremental Cost-Effectiveness Ratio (ICER) of screening colonoscopy compared to no screening for adult patients was found to be cost-effective and valued at USD 6,191.15/QALY (Quality-adjusted Life Year). This value was significantly below the Cost-Effectiveness Threshold (CET) assumed to be USD 14,759.10. Based on the cost-effectiveness acceptability curve at a willingness to pay (WTP) threshold of USD 5,500, the probability of being cost-effective for colorectal cancer screening increased and consistently reached 100% at a WTP level of USD 9,000. Colonoscopy screening was cost-effective when analyzed using the Markov model, as suggested by ICER value exceeding three times the Gross Domestic Product (GDP) of Indonesia. Future research could explore alternative interventions, such as biennial colonoscopy, and compare the result with other screening methods.

  • Systematic Review: Effectiveness, Safety, and Quality of life for Diabetic Foot Ulcer patients with Hyperbaric Oxygen Therapy

    by Faizah Ana K., Libriansyah Libriansyah, Dwi Endarti, Andayani Tri M.

    Diabetic foot ulcers are often associated with amputation of the lower extremities. Hyperbaric oxygen therapy is considered an adjuvant to accelerate wound healing and reduce the number of amputations in diabetic foot ulcer patients. The systematic review aimed to confirm the effect of hyperbaric oxygen therapy as an adjunct therapy in diabetic foot ulcer patients. PUBMED, SCOPUS, and COCHRANE will be used as databases. Eligible articles include those that compare hyperbaric oxygen therapy with standard therapy in diabetic foot ulcer patients published until March 2024. The main outcomes measured include wound healing, incidence of amputation, side effects, mortality, and quality of life. Two reviewers independently screened, extracted data, and assessed the risk of bias for the included papers. The COCHRANE system and ROBINS-I were used to assess the quality of studies. The search yielded 953 results, of which 39 full-text articles were evaluated for relevance. Sixteen studies met the inclusion criteria. Thirteen studies were randomized controlled trials. There were significant differences in wound healing and major amputations, whereas there were no significant differences in minor amputations. Six studies reported side effects of barotrauma and two studies reported no side effects in patients. Hyperbaric oxygen therapy improves wound healing and major amputations compared to standard therapy. Further research is needed, especially regarding patient criteria and the number of hyperbaric oxygen therapy sessions to be able to determine which one gets the most effective.

  • Open Access

    Pharmacist-Led Patient Education in Secondary Stroke Prevention: A Systematic Review

    by Daniek Viviandhari, Tri Murti Andayani, Paryono Paryono, Martina Sinta Kristanti

    The recurrence rate of stroke, particularly ischaemic stroke, is considered high, which highlights the importance of secondary stroke prevention. Pharmacists are becoming increasingly involved in poststroke care. Ease of public access to community pharmacists provides opportunities for pharmacists to educate patients about the significance of secondary stroke prevention. The literature outlining comprehensive educational materials for stroke patients to prevent secondary stroke is still limited. This review aimed to obtain the details of the educational material presented by the pharmacist and to determine whether it led to positive outcomes—a comprehensive search involved PubMed, Scopus, Science Direct, and Cochrane Library databases. The Joanna Briggs Institute’s (JBI) critical appraisal techniques were utilised to analyse the quality assessment for all study categories. As many as 12 studies were deemed eligible for inclusion. There are seven main categories under which information on secondary stroke prevention education is presented: modifiable risk factors, medication therapy management (MTM), medication adherence, cardiovascular risk factors, stroke (disease state), patient engagement, and quality of life. Pharmacists, mostly in community settings, play an important role in managing stroke risk factors (blood pressure, low-density lipoprotein [LDL], and A1c), promoting medication adherence, preventing hospital readmissions, increasing the level of knowledge, and enhancing patient satisfaction, which showed a favourable effect on preventing stroke recurrence following the pharmacist’s educational intervention.

  • Open Access

    Evaluasi Penggunaan Antibiotik Empiris pada Pasien Sepsis di Intensive Care Unit RSUD Dr. H. Abdul Moeloek Provinsi Lampung

    by Desy Purnamasari, Nanang Munif Yasin, Tri Murti Andayani

    Sepsis merupakan kondisi mengancam jiwa yang terjadi akibat adanya penurunan fungsi organ yang berkaitan dengan infeksi. Salah satu terapi yang diberikan pada awal diagnosis sepsis dan menentukan keberhasilan terapi selanjutnya adalah pemberian antibiotik. Penggunaan antibiotik yang tidak tepat berkaitan dengan kejadian resistensi dan dapat menyebabkan peningkatan keparahan penyakit, peningkatan biaya perawatan, komplikasi dan bahkan kematian. Penelitian ini bertujuan untuk mengevaluasi penggunaan antibiotik empiris pada pasien sepsis di ICU. Penelitian ini merupakan observasional analitik dengan desain cohort retrospectiive. Subyek penelitian ini didapatkan dari data rekam medik pasien dengan diagnosis sepsis yang dirawat di ICU RSUD Dr. H. Abdul Moeloek pada Januari 2019 – Agustus 2024. Evaluasi antibiotik dilakukan secara kualitatif dan dikaji berdasarkan literatur dengan metode Gyssens. Hasil penelitian ini adalah 123 pasien dengan 192 regimen antibiotik empiris. Antibiotik yang paling banyak diresepkan adalah ceftriaxone (37,5%) dengan indikasi penyebab sepsis terbanyak adalah pneumonia (76,6%). Hasil analisis gyssens terdapat 134 regimen (69,8 %) yang tepat dan 58 regimen (30,2%) dinilai tidak tepat dengan kategori V (tidak ada indikasi penggunaan antibiotik) sebanyak 10 kasus (5,2%), kategori IVa (ada antibiotik lain yang lebih efektif) sebanyak 25 kasus (13,0%), kategori IIIa (durasi pemberian terlalu panjang) sebanyak 14 kasus (7,3%), kategori IIIb (durasi pemberian terlalu singkat) sebanyak 3 kasus (1,6%), kategori IIa (dosis tidak tepat) sebanyak 5 kasus (2,6%) dan kategori IIb (interval tidak tepat) sebanyak 1 kasus (0,5%). Penelitian ini menunjukkan bahwa penggunaan antibiotik secara tepat dan rasional perlu ditingkatkan.


  • Open Access

    Medication-related Burden and Experience With Medications in Indonesian Older Adults With Chronic Diseases: A Mixed-method Study

    by Yeni Farida, Anna Wahyuni Widayanti, Tri Murti Andayani, Probosuseno Probosuseno

    Objectives: This study explored the specific medication-related burdens experienced by older adults with chronic disease and the contributing factors.Methods: An exploratory mixed-method study was conducted at a teaching hospital in Surakarta City, Central Java, Indonesia. Combining the Indonesian version of the Living with Medicine Questionnaire (LMQ) and semi-structured interviews allowed for a comprehensive understanding of the medication-related burden. Differences in LMQ scores related to patient characteristics were analyzed using the t-test, F-test, or other alternatives. Quantitative and qualitative data triangulation was used to derive trustworthy and dependable results.Results: The overall LMQ mean score was 90.4 (n=129), indicating a moderate burden. The average LMQ scores varied significantly based on the number of medications, treatment duration, and the presence of cardiovascular disease (CVD), diabetes mellitus (DM) and stroke. The qualitative study found 3 themes in the chronic medication use of older adults: experiences, challenges, and motivation. Despite their limited understanding of a medication’s name and indication, some patients managed their medications based on the physical look and packaging of the medication. The study also found that patient motivation and familial support could effectively counteract the fatigue and dissatisfaction associated with taking medication.Conclusions: Older adults with chronic diseases faced medication-related burdens associated with the presence of CVD, DM, stroke, a treatment duration >5 years, and the use of >10 medications. Effective communication with healthcare professionals is required to understand patients’ needs and concerns, thereby helping manage the challenges of medication-related burdens.